Sponsored by www.dsm.com PHARMACEUTICAL EXECUTIVE 40 Will the recent wave of megamergers and a slow revival of biotech financing be enough to counter a looming storm surge of patent expirations? US health reform is the next big game-changer, as companies seek a balance between earning profits and placating a restive new breed of payers and the ever-expectant patient By Jerry Cacciotti and Patrick Clinton 40 PHARMACEUTICAL EXECUTIVE
12
Embed
Pharmaceutical Executive Top 50 Pharma Companies Report
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Sponsored bywww.dsm.com
Sponsored bywww.dsm.com
PHARMACEUTICAL EXECUTIVE40
Will the recent wave of megamergers and a slow revival of biotech fi nancing be enough to counter a looming storm surge of patent expirations? US health reform is the next big game-changer, as companies seek a balance between earning profi ts and placating a restive new breed of payers and the ever-expectant patient
The Pharm Exec 50 ranks the world’s largest pharmaceutical companies by global sales of pre-
scription drugs—a key indicator of market change. After last year’s storm of activity, the 50 set a more placid pace, as major players worked on inte-grating blockbuster mergers and licked their wounds after the latest round of Phase III failures. Late-phase problems are nothing new, and drug candidates can come back from them, but there was something particularly heartbreak-ing about the recent crop of dead ends, given the huge unmet medical need as-sociated with these therapies: P� zer’s Dimebon and Lilly’s Semagacestat for Alzheimer’s, Merck’s vicriviroc for HIV, and Roche’s ocrelizumab for rheuma-toid arthritis, to name just a few.
Change was most visible on the macro level. The list of the top 10 com-panies was shaken up a bit, with No-vartis passing Sano� -Aventis to move into second place, and Merck jumping from seventh to fourth. It was also the � rst year the top company crossed the $50 billion mark in sales of prescrip-
tion drugs—as P� zer, fueled by its ac-quisition of Wyeth, grew from $45.4 billion in Rx sales to $58.5 billion. Meanwhile, consolidation in the ranks continues to place a premium on size and scale: This was the � rst year that it took $2 billion in Rx revenues to join the 50. As recently as 10 years ago, you could make the list with revenues of only $500 million.
Overall, the 50 accounted for $593.4 billion in human prescription drug sales in 2010. That represents an increase of nearly 8 percent from 2009, when the total was $550.5 billion. But among the top 10, there was slightly better growth. This year’s group grew its Rx revenues from $319.4 billion in � scal 2009 to $352.5 last year—an in-crease of over 10 percent.
A good percentage of that growth was fueled by mergers and acquisi-tions. In addition to P� zer and its 29 percent increase, big gainers included Merck (58 percent growth after its merger with Schering Plough) and Ab-bott (up nearly 28 percent in the wake of its acquisitions of Solvay and Pira-
mal). But the biggest single-year bump came at a much smaller company: The Irish � rm Warner Chilcott last year ac-quired the pharmaceutical business of Procter & Gamble, including the bil-lion-dollar drug Actonel, and raised its Rx revenues a whopping 111 percent to $2.9 billion.
Looming over the year—and the decade—is the shadow of US health-care reform. Many in pharma feel they have dodged the bullet of new regula-tion and stand to gain as a projected 30 million previously uninsured Amer-icans � nally obtain insurance coverage for healthcare. But the Patient Protec-tion and Affordable Care Act is not the end of the discussion—it’s more like the beginning of an avalanche. The economic forces it sets in motion today will be playing out for payers, patients, providers, and pharma for the foresee-able future, changing the way care is delivered and paid for, creating numer-ous business threats, but, with luck, ending up with the possibility of get-ting a better alignment between help-ing the patient and earning a pro� t.
Revenue Distribution of Top 50
Top 10 accounts for $352.5 billion in sales, which is 59.40% of total revenues of the Top 50
Top 20 accounts for $483.8 billion in sales, which is 81.53% of total revenues of the Top 50
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded
How the listings were compiled: Companies in the Pharm Exec 50 are ranked according to global human prescription drug sales. As far as company documentation allows, generics and vaccines are included; over-the-counter products, royalties, and contract manufacturing revenue are not. In most cases, numbers are taken from annual reports or SEC filings for the fiscal year that ended in 2010. For most American and European companies, that means the year ending Dec. 31, 2010; for many Japanese companies, it means the year ending March 31, 2010. In the case of private companies that do not report results, we have made estimates based on available data, including IMS reports. For companies that report in currencies other than US dollars, we have converted their numbers using the midpoint average interbank rate for the last day of the fiscal year. Some charts that accompany this article are based on numbers from IMS Health. These are based on a different methodology and will not be consistent with the figures we have compiled from financial filings. Percentage growth figures should be treated with caution, because they can be affected by fluctuating exchange rates.
Sponsored bywww.dsm.com
PHARMACEUTICAL EXECUTIVE44
Latin AmericaJapan
Asia/Africa/AustraliaEurope
North America
Latin AmericaJapan
Asia/Africa/AustraliaEurope
North America
42.3%
29.2%
12.4%
10.8%
5.3%
25 Spiriva Handihaler
24 Copaxone
23 Atripla
22 Lovenox
21 Aricept
20 Rituxan
19 Lexapro
18 Humira
17 Zyprexa
16 Neulasta
15 Oxycontin
14 Avastin
13 Cymbalta
12 Enbrel
11 Remicade
10 Epogen
9 Actos
8 Crestor
7 Singulair
6 Seroquel
5 Abilify
4 Advair Diskus
3 Plavix
2 Nexium
1 Lipitor
Sou
rce:
IMS
Hea
lth,
MID
ASS
ourc
e: IM
S H
ealt
h
Global Pharma Sales by Region Market Share Region USD in Billions Growth from 2009
Top 25 US Pharma Products by Sales Product 2010 2009 % Change
Sales represent audited market for pharma products only (Dec. 2009–Dec 2010)IMS fi gures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
Figures (rounded) in US billions
Worldwide Totals: $791.4 4.2%
TOTAL US SCRIP MARKET: 2010: $307.4 2009: $300.3 2.36%
Figures (rounded) in USD billionsTherapy Class defi ned using ATC-defi ned product groups and synthesized based on proprietary IMS Health defi nitons
Immunostimulating Agents excludes interferons
Rx fi gures (rounded) in millions;Therapy classes defi ned using ATC defi ned product groups and synthesized based on proprietary IMS Health defi nitions
Sou
rce:
IMS
Hea
lth
Sou
rce:
IMS
Hea
lth
TOTAL US SCRIP MARKET: 2010: 3,995.2 2009: 3,949.2 1.16%
TOTAL US SCRIP MARKET: 2010: $307.4 2009: $300.3 2.36%
Sponsored bywww.dsm.com
Sponsored bywww.dsm.com
PHARMACEUTICAL EXECUTIVE50
2011 Rank
Company HQ [website]
2010 Rx Sales (USD
billions) [% change from 2009]
2010 R&D spend(USD Millions)
2010 Top-Selling Drugs [USD billions]
21 Merck KGaA Darmstadt, Germany [merck.de]
$7.8 [–0.4%] $1,547 Rebif [2.2]
22 Gilead Sciences Foster City, California [gilead.com]
$7.4 [14.2%] $1,073 Atripla [3.0]
23 Baxter International Deerfield, Illinois [baxter.com]
$5.6 [1.3%] $915 Advate [1.7]
24 Mylan Canonsburg, Pennsylvania [mylan.com]
$5.2 [7.5%] $282 EpiPen [0.3]
25 Servier Neuilly-sur-Seine [servier.com]
$4.9 [6.6%] $1,226 Coversil [1.5*]
26 Chugai Tokyo, Japan [chugai-pharm.co.jp]
$4.6 [1.3%] $671 Avastin [0.6]
27 Mitsubishi Tanabe Osaka, Japan [mt-pharma.co.jp]
$4.4 [2.4%] $897 Remicade [0.5]
28 Menarini Florence, Italy [menarini.com]
$4.0* [0.2%] N/A Migard/Allegro [0.1*]
29 Genzyme Cambridge, Massachusetts [genzyme.com]
$4.0 [2.3%] $847 Cerezyme [0.7]
30 Allergan Irvine, California [allergan.com]
$4.0 [7.9%] $805 Botox [1.4]
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded
Sales fi gures (rounded) in USD millions; Rx fi gures rounded LOE = Loss of Exclusivity
Figures (rounded) in USD billions (Dec 2009–Dec 2010)Sales represent audited market for pharma products only
IMS fi gures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
Figures (rounded) in USD millions (Dec. 2009–Dec. 2010) Sales represent audited market for pharma products only Figures do not account for off-invoice discounts/rebates and can vary from reported mfr sales
TOTAL US SCRIP MARKET: 2010: $408.3 2009: $384.9 6.10%
TOTAL US SCRIP MARKET: 2010: $123,315.5 2009: 116,221.7 6.10% Increase
Sponsored bywww.dsm.com
PHARMACEUTICAL EXECUTIVE56
2011 Rank
Company HQ [website]
2010 Rx Sales (USD
billions) [% change from 2009]
2010 R&D spend(USD Millions)
2010 Top-Selling Drugs [USD billions]
41 Watson Corona, California [watson.com]
$2.6 [27.0%] $296 CNS generics [0.9]
42 Lundbeck Copenhagen, Denmark [lundbeck.com]
$2.6 [–0.6%] $542 Cipralex/Lexapro [1.5]
43 Kyowa Hakko Kirin Tokyo, Japan [kyowa-kirin.co.jp]
$2.6 [14.7%] $429 Nesp/Espo [0.6*]
44 Dainippon Sumitomo Osaka, Japan [ds-pharma.co.jp]
$2.6 [20.1%] $554 Amlodin [0.6]
45 Shionogi Osaka, Japan [shionogi.co.jp]
$2.4* [35.2%] $135 Crestor [0.3]
46 Actavis Hafnarfjörður, Iceland [actavis.com]
$2.4* [32.5%] N/A Oxycodone [0.4]
47 Hospira Lake Forest, Illinois [hospira.com]
$2.3 [13.3%] $301 N/A [N/A]
48 Nycomed Zurich, Switzerland [nycomed.com]
$2.2 [–20.2%] $281 Pantoprazole [1.2]
49 Apotex North York, Ontario, Canada [apotex.com]
$2.1* [–19.2%] N/A N/A [N/A]
50 Stada Bad Vilbel, Germany [stada.de]
$2.1 [–5.0%] $73 Generic omeprazole [0.1]
Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded
1. Pfizer President and CEO Jeff Kindler retired, succeeded by Ian C. Read. George Lorch elected Non-Execu-tive Chairman of the Board. Sutent ap-proved in EU for treatment of pancreatic neuro-endocrine tumors. Launched Prevnar 13, a vaccine against 13 strains of pneumococcal diseases in infants and young children. Also has 118 products in the R&D pipeline and had 1,300 clinical trials in 2010.
2. Novartis Completed purchase of Alcon from Nestlé for $38.7 billion. Jonathan Symonds promoted to CFO. David Epstein replaced CEO Joe Jimenez as Division Head, Pharmaceuticals. Thirteen major pharmaceutical approvals in the US, Europe, and Japan, with 147 products in development. Tasigna was ap-proved in the US, the EU, Japan, and Swit-zerland for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a form of blood cancer. Menveo (vaccine against meningococcal disease) launched in the US, EU, and parts of Latin America and Asia. Sandoz launched generic enoxaparin, its most successful launch to date, and acquired Oriel Therapeutics.
3. Sanofi-Aventis Initiated acquisition of Genzyme for $16.6 billion (completed in April) and finished acquisition of OTC company Chattem. Began collaboration programs with Harvard and Columbia Universities and a research alliance with Scripps Genomic Medicine. Jevtana approved in US for second-line treatment of metastatic hormone-refractory prostate cancer.
4. Merck Elected Kenneth Frazier CEO. Bought Inspire for $430 million. Rotateq vaccine awarded top honor at Prix Galien USA 2010. Merck BioVentures entered into an alliance with Parexel for biosimilar devel-opment. Signed commercialization agree-ment with Lundbeck for Sycrest and a letter of mutual intent with China’s Sinopharm. Pipeline has more than 20 late-stage can-didates. Licensed oral mTOR inhibitor for multiple cancers from Ariad. Oral hepatitis C protease inhibitor Boceprevir granted Priority Review status by FDA.
5. Roche Rituxan approved in US as first-line treatment for chronic lymphocytic leukemia (CLL) and relapsed/refractory CLL. Tarceva approved in US and EU for first-line treatment of non-small-cell lung cancer after chemotherapy. FDA rejected use of Avastin as a treatment for metastatic breast cancer; Roche has requested a hearing to appeal this decision. Daniel O’Day appointed COO of the Pharmaceuticals division. Alan Hippe named CFO. Jean-Jacques Garaud appointed Head of Roche Pharma Research and Early Development.
6. GlaxoSmithKline Benlysta (belimumab, the first new lupus treatment in 60 years) approved by FDA in March. Six products in total approved by US and EU; seven more filed with regulators. Malaria vaccine in Phase III trials in Africa, with 30 other late-stage assets. Julian Heslop retired as CFO, succeeded by Simon Dingemans. Patents for active ingredients in Seretide/Advair expired.
7. AstraZeneca Crestor substance patent upheld in US court. Approvals include Vimovo (naproxen/esomeprazole magnesium) in US and EU and Brilique (atherothrombotic event prevention) in
EU. Kombiglyze XR, the only once-daily dose of DPP4/metformin, developed with Bristol-Myers Squibb, also approved in US. Nine molecules in Phase III trials or submitted for regulatory approval, with another 92 projects in development. Com-pleted deal with Rigel for development of fostamatinib (rheumatoid arthritis).
8. Johnson & Johnson Completed tender offer for Crucell N.V. in February 2011; acquired 98.93 percent of shares. Products under regulatory review include: Rivaroxoban for stroke prevention in pa-tients with atrial fibrillation (US), Telaprevir for hepatitis C (US and EU), Abiraterone acetate for metastatic advanced prostate (US and EU), and rilpivirine for HIV. Eight more candidates planned for regulatory submission from 2011 to 2013.
9. Eli Lilly Completed acquisition of Alnara and Avid Radiopharmaceuticals. Launched statin Livalo in the US with part-ner Kowa. Has 68 molecules in develop-ment. Several monoclonal antibodies for cancer in late-stage development. Phase III candidates include Necitumumab for non-small-cell lung cancer and Ramu-cirumab for metastatic breast and gastric cancers. Signed commercialization deal with Acrux for newly approved experimen-tal testosterone solution Axiron.
10. Abbott The year was marked by acquisitions, including the pharmaceuti-cal business of Solvay for $6.1 billion plus milestones, and Piramal Healthcare’s Healthcare Solutions business, a leader in the Indian branded generics market, for $2.2 billion in cash, plus $1.6 billion in annual payments through 2014. Additional acquisitions included Advanced Medical Op-tics, STARLIMS Technologies (informatics), and the remaining shares of Facet Biotech.
The Top 10 Year In Review
Jerry Cacciotti is a Partner in Oliver Wyman’s Health and Life Sciences Practice. He can be reached at [email protected]
Patrick Clinton is Marketing Director in the Health & Life Sciences practice of Oliver Wyman. He can be reached at [email protected]